

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC**

**CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

**VOLUNTARY ANNOUNCEMENT**

**APPROVAL GRANTED FOR THE COMMENCEMENT OF  
CLINICAL TRIALS FOR THE GROUP'S PRODUCTS**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has recently been granted approval from the China Food and Drug Administration to commence clinical trials for the following products developed by the Group.

<b>Drug Name</b>	<b>Registration Type</b>	<b>Indications</b>
1. Paclitaxel for injection (albumin-bound)	Chemical drug type 1.6	Pancreatic cancer
2. Paclitaxel for injection (albumin-bound)	Chemical drug type 3.4	Non-small cell lung cancer
3. Vilazodone hydrochloride tablets	Chemical drug type 3.1	Depression
4. Lurasidone hydrochloride tablets	Chemical drug type 3.1	Schizophrenia
5. Fosaprepitant dimeglumine for injection	Chemical drug type 3.1	Nausea
6. Tebipenem pivoxil granules	Chemical drug type 3.1	Anti-infection
7. Doripenem for injection	Chemical drug type 3.1	Anti-infection
8. Esomeprazole magnesium enteric-coated capsules	Chemical drug type 5	Gastro-esophageal reflux disease
9. Gefitinib tablets	Chemical drug type 6	Non-small cell lung cancer

	<b>Drug Name</b>	<b>Registration Type</b>	<b>Indications</b>
10.	Dasatinib tablets	Chemical drug type 6	Philadelphia chromosome-positive chronic myelocytic leukemia
11.	Sunitinib malate capsules	Chemical drug type 6	Kidney cancer; Gastrointestinal stromal tumors; Pancreatic neuroendocrine tumors
12.	Sorafenib tosylate tablets	Chemical drug type 6	Late stage renal cell carcinoma; Distant metastasis of primary hepatocellular carcinoma
13.	Glipizide extended-release tablets	Chemical drug type 6	Type II diabetes
14.	Metformin hydrochloride tablets	Chemical drug type 6	Type II diabetes
15.	Sitagliptin phosphate tablets	Chemical drug type 6	Type II diabetes
16.	Rabeprazole sodium enteric-coated capsules	Chemical drug type 6	Gastro-esophageal reflux disease: erosive reflux esophagitis
17.	Lansoprazole enteric-coated capsules	Chemical drug type 6	Gastro-esophageal reflux disease: erosive reflux esophagitis
18.	Pramipexole hydrochloride tablets	Chemical drug type 6	Parkinson's disease
19.	Risperidone tablets	Chemical drug type 6	Schizophrenia
20.	Clopidogrel hydrogen sulfate tablets	Chemical drug type 6	Prevent the formation of atherosclerosis
21.	Nifedipine controlled-release tablets	Chemical drug type 6	Hypertension; Coronary heart disease; Chronic stable angina
22.	Rivaroxaban tablets	Chemical drug type 6	Antithrombotic agent
23.	Ticagrelor tablets	Chemical drug type 6	Coronary syndrome
24.	Irbesartan hydrochlorothiazide tablets	Chemical drug type 6	Primary hypertension
25.	Glucosamine hydrochloride capsules	Chemical drug type 6	Treatment and prevention of osteoarthritis
26.	Amoxicillin and clavulanate potassium tablets	Chemical drug type 6	Anti-infection
27.	Amoxicillin and clavulanate potassium dispersible tablets	Chemical drug type 6	Anti-infection
28.	Cefdinir capsules	Chemical drug type 6	Anti-infection

The approval for commencement of clinical trials is expected to provide an impetus to the drug development of the Group and lay a foundation for the Group to further enrich its product portfolio.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 5 February 2016

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam and Mr. YU Jinming as independent non-executive directors.*